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The prevalence of head and neck cancers in the USA is
estimated to be about 370,000 and between 25% to 38%
of these are human papilloma virus (HPV)-associated
head and neck squamous cell carcinomas (HNSCC). We
have developed a viral gene delivery platform to immu-
nize against HPV 16 genes E6 and E7 (Ad5 [E1-, E2b-
]-E6/E7) for the treatment of HPV-associated HNSCC.
We tested the Ad5 [E1-, E2b-]-E6/E7 immunotherapy
alone and in combination with programmed death-
ligand 1 (PD-1) blockade in a murine HPV+ tumor
model. As a single agent, Ad5 [E1-, E2b-]-E6/E7 induced
HPV-E6/E7 cell-mediated immunity and resulted in the
clearance of small tumors and an overall survival benefit
in mice with larger established tumors. When immu-
notherapy was combined with PD-1 immune checkpoint
blockade, an increased level of anti-tumor activity
against large tumors was observed in addition to an
improvement in survival. Tumor microenvironment ana-
lysis in Ad5 [E1-, E2b-]-E6/E7 treated mice revealed an
increase in CD8+ tumor-infiltrating lymphocytes (TILs).
In addition, we observed induction of suppressive
mechanisms such as programmed death-ligand 1 (PD-
L1) expression on tumor cells and an increase in PD-1+
TILs. When Ad5 [E1-, E2b-]-E6/E7 immunotherapy was
combined with anti-PD-1 antibody, we observed CD8+
TILs at the same increased level but found that a smal-
ler fraction of these were PD-1+. Furthermore, we
observed a reduction in PD-L1 expression on tumor
cells, providing a mechanism by which combination
therapy favors tumor clearance and a rationale for pair-
ing antigen-specific vaccines with checkpoint inhibitors
in future clinical trials.
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